Go back

Pharma R&D costs up due to tougher targets and stronger regulation

The cost of developing a new medicine has increased from £125 million to £1.2 billion in the last 30 years, according to a report released by the Office of Health Economics.

It suggests the increase is due, in part, to the fact that “tougher” therapeutic areas are being addressed now, so success rates have fallen. Tighter regulations have also added years on to the R&D stages of projects, which now take around 13.5 years, compared with six years in the 1970s.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.